A Post Marketing Surveillance on Piqray in Korea

This is a post-marketing surveillance study monitoring how a drug called Piqray (alpelisib) performs in real-world use in South Korea. It tracks safety and outcomes in breast cancer patients who are already being prescribed this drug as part of their standard care. **You may be eligible if...** - You are a postmenopausal woman or a man - You have hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer (confirmed by testing) - Your cancer has progressed after hormone-based therapy - You are about to start Piqray for the first time - You are willing to provide written informed consent **You may NOT be eligible if...** - You have a contraindication to Piqray (e.g., severe allergy to it) - You have been previously treated with Piqray - You have type 1 or uncontrolled type 2 diabetes Talk to your doctor to see if this trial is right for you.